Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare

Conditions

Diseases of the Integumentary System

Phase Pilot

What is the purpose of this trial?

Brief Summary:

To investigate the ability of tofacitinib, a Janus kinase (JAK) inhibitor, to treat patients with cutaneous sarcoidosis and granuloma annulare during 6 months of therapy.

  • Trial with
    Pfizer Inc., U.S. Pharmaceuticals Group
  • Start Date
    04/07/2019
  • End Date
    08/30/2020

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Yvette Strong

Principal Investigator

Sub-Investigator

  • Last Updated
    07/15/2019
  • Study HIC
    #2000023910